Online inquiry

IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13804MR)

This product GTTS-WQ13804MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ13804MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13023MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ14336MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG7414
GTTS-WQ3132MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA APT070
GTTS-WQ8712MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ413MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ14625MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SC0001
GTTS-WQ1487MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ13519MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PRX002
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW